LLY

754.8

+2.95%↑

JNJ

154.98

+0.66%↑

UNH

379.64

-0.19%↓

ABBV

191.89

+4.15%↑

ABT

133.55

+0.22%↑

LLY

754.8

+2.95%↑

JNJ

154.98

+0.66%↑

UNH

379.64

-0.19%↓

ABBV

191.89

+4.15%↑

ABT

133.55

+0.22%↑

LLY

754.8

+2.95%↑

JNJ

154.98

+0.66%↑

UNH

379.64

-0.19%↓

ABBV

191.89

+4.15%↑

ABT

133.55

+0.22%↑

LLY

754.8

+2.95%↑

JNJ

154.98

+0.66%↑

UNH

379.64

-0.19%↓

ABBV

191.89

+4.15%↑

ABT

133.55

+0.22%↑

LLY

754.8

+2.95%↑

JNJ

154.98

+0.66%↑

UNH

379.64

-0.19%↓

ABBV

191.89

+4.15%↑

ABT

133.55

+0.22%↑

Kodu・Aktsiate loetelu・Mirati Therapeutics Inc

Mirati Therapeutics Inc

Avatud

SektorTervishoid

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

Max

Soovitused
By TipRanks
Soovitused	Neutraalne
12 kuu keskmine prognoos	-0.05% downside

Uudiste sentiment

By Acuity

43%

57%

147 / 382 Pingereas Healthcare

Mirati Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

11. mai 2025, 23:48 UTC

Tulu

Omandamised, ülevõtmised, äriostud

Dyno Nobel Returns to 1st Half Profit; Strikes Fertilizers Deals -- Update

11. mai 2025, 23:46 UTC

Market Talk

Nikkei May Rise on Hopes for U.S.-China Trade Talks -- Market Talk

11. mai 2025, 23:45 UTC

Market Talk

Oil Rises Amid Improved Market Mood -- Market Talk

11. mai 2025, 23:38 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Aristocrat Has Significant Firepower for M&A -- Market Talk

11. mai 2025, 23:36 UTC

Market Talk

Global Markets Uncertain About US-China Trade News -- Market Talk

11. mai 2025, 23:35 UTC

Market Talk

Gold Falls, Dragged by Weakening Safe-Haven Demand, Possible Profit-Taking -- Market Talk

11. mai 2025, 23:33 UTC

Tulu

Omandamised, ülevõtmised, äriostud

Dyno Nobel Returns to 1H Profit; Strikes Fertilizers Deals -- Update

11. mai 2025, 23:32 UTC

Peamised uudised

Proposal Cutting Medicaid Aims for GOP Middle Ground -- WSJ

11. mai 2025, 22:44 UTC

Market Talk

Centaurus Metals's Jaguar Project Faces Funding Hurdles -- Market Talk

11. mai 2025, 22:33 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Domain Takeover Could Create Near-Term Overhang on REA Stock -- Market Talk

11. mai 2025, 20:19 UTC

Peamised uudised

Bessent Says U.S.-China Trade Talks Were 'Productive,' Without Offering Specifics -- WSJ

11. mai 2025, 16:00 UTC

Peamised uudised

Trump's Budget Hawk Takes Over the DOGE Agenda. First Up: the Military -- WSJ

11. mai 2025, 11:00 UTC

Peamised uudised

This Obscure New York Court Is Set to Decide Fate of Trump's Tariffs -- WSJ

11. mai 2025, 08:00 UTC

Peamised uudised

China's Property Market Is a Tale of Big Cities. Everywhere Else Is Struggling. -- Barrons.com

11. mai 2025, 01:00 UTC

Peamised uudised

The Spring Home Sales Season Is Shaping Up to Be a Dud -- WSJ

11. mai 2025, 01:00 UTC

Peamised uudised

Europe Threatens Nord Stream 2 Sanctions to Pressure Russia on Cease-Fire -- WSJ

10. mai 2025, 21:54 UTC

Peamised uudised

GOP Tax Bill Seeks to Put Cash in Taxpayers' Pockets in Early 2026 -- Update

10. mai 2025, 17:12 UTC

Peamised uudised

Europe Threatens Nord Stream 2 Sanctions to Pressure Russia to Cease Fire -- WSJ

10. mai 2025, 15:41 UTC

Peamised uudised

Fed Officials Signal Pause on Adjusting Interest Rates as Trade Risks Mount -- Barrons.com

10. mai 2025, 12:00 UTC

Peamised uudised

Why a Sorority Is Taking on Trump's Budget Cuts -- WSJ

10. mai 2025, 09:30 UTC

Peamised uudised

The Giants of Silicon Valley Are Having a Midlife Crisis Over AI -- WSJ

10. mai 2025, 08:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

10. mai 2025, 03:52 UTC

Peamised uudised

China Struggles With Persistent Disinflationary Pressures as Tariffs Bite -- WSJ

9. mai 2025, 23:51 UTC

Omandamised, ülevõtmised, äriostud

Oil at $50? The High Cost of Cheap Crude. -- Barrons.com

9. mai 2025, 22:06 UTC

Market Talk

Arm Holdings Remains a Strong Growth Story -- Market Talk

9. mai 2025, 21:37 UTC

Peamised uudised

U.S. Sets August Deadline for Debt Ceiling -- WSJ

9. mai 2025, 21:10 UTC

Peamised uudised

The Score: Disney, Berkshire Hathaway, Ford and More Stocks That Defined the Week -- WSJ

9. mai 2025, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

9. mai 2025, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

9. mai 2025, 20:42 UTC

Peamised uudised

Stocks Get a Break From Trade Chaos -- WSJ

Võrdlus sarnastega

Hinnamuutus

Mirati Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

-0.05% langus

12 kuu keskmine prognoos

Keskmine 58.67 USD -0.05%

Kõrge 59 USD

Madal 58 USD

Põhineb 5 Wall Streeti analüütiku instrumendi Mirati Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

5 ratings

Osta

Hoia

Müü

Põhineb 5 analüütiku instrumendi Mirati Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

147 / 382 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

EBITDA

Ärikasum

Ettevõttest Mirati Therapeutics Inc

Mirati Therapeutics, Inc. is a clinical-stage oncology company. It is focused on developing therapeutics to address the genetic and immunological promoters of cancer. Its clinical programs consist of product candidates, including Adagrasib (MRTX849), MRTX1133, and Sitravatinib. MRTX849 is an oral small-molecule therapy designed to shrink difficult-to-treat cancers harboring the KRAS G12C mutation. MRTX1133 is a small molecule-inhibitor of the KRASG12D mutation, designed to treat patients with unmet need. Sitravatinib is a spectrum-selective receptor tyrosine kinase (RTK) inhibitor that can stimulate the body’s immune response to fight cancer. MRTX849 is in Phase III and Phase I/II clinical trials and MRTX1133 is in preclinical development. Sitravatinib is in a Phase III clinical trial, and Phase I/II clinical trials. It also has additional preclinical discovery programs, which includes first-in-class and best-in-class product candidates designed to address mutations and tumors.